A week ago players in the CAR-T space may have been right in thinking Imugene needs us to enable Oncarlytics to achieve everything it might.
It could just be that scales of any future license negotiations for Oncarlytics have shifted significantly Imugene's way,
Whilst Imugene is certainly taking on some further risk, the stakes in this game have certainly been lifted.
I think Imugene is absolutely certain that CF33 as a guided missle system works without a doubt.
Ignoring for a moment any mention of CF33 as a cancer killer and attach to it a payload .... one way or another something is going to go KABOOM.
I certainly am happy to wait for that day.
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-346
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
-0.003(4.84%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 6.1¢ | 6.3¢ | 5.8¢ | $2.926M | 48.68M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 1489666 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 1250588 | 5 |
View Market Depth
| Last trade - 16.10pm 04/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |